Cardionomic
Cardionomic is a Minneapolis-based company focused on transforming treatment for Acute Decompensated Heart Failure (ADHF) through its investigational Cardiac Pulmonary Nerve Stimulation (CPNS™) System.
Company Overview
Cardionomic is dedicated to revolutionizing treatments for Acute Decompensated Heart Failure (ADHF). Based in Minneapolis, the company is at the forefront of innovative therapies aimed at improving heart failure management. Cardionomic collaborates with healthcare partners to develop effective treatments, addressing the needs of over 25 million people worldwide suffering from heart failure.
Cardiac Pulmonary Nerve Stimulation (CPNS™) System
The CPNS™ System by Cardionomic is under investigation for treating ADHF patients. The CPNS Catheter is strategically placed in the right pulmonary artery to deliver temporary, targeted electrical stimulation to surrounding nerves. This system aims to increase cardiac contractility while maintaining a neutral effect on heart rate. The CPNS System has been evaluated through multiple studies, underlining its potential to enhance heart failure treatment.
Clinical Studies on CPNS System
Cardionomic has conducted extensive clinical research to assess the safety and efficacy of the CPNS System. The STIM-ADHF and STOP-ADHF pilot studies focused on evaluating the system in hospitalized ADHF patients across various regions including the United States, the European Union, and Panama. Additionally, the CPNS 2 Feasibility Study explored the short-term safety and feasibility of the system in patients with chronic heart failure over a duration of 1-3 hours. These studies are pivotal in proving the system's capabilities.
Funding and Corporate Growth
Cardionomic secured $20 million in Series A financing in October 2015, signaling strong investor confidence in their innovative approach to heart failure treatment. This significant funding milestone has enabled Cardionomic to further its research and development, ensuring continuous progress in their clinical trials and product offerings.
Global Reach and Research Collaborations
Cardionomic's research and clinical studies have a global footprint, including countries like the United States, Slovakia, and Panama. The company conducted the first U.S. enrollment in the CPNS Pilot Study at The Ohio State University Wexner Medical Center. Such widespread collaboration highlights Cardionomic's commitment to advancing heart failure treatments through international research partnerships and clinical trials.